Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its ...
Decreased strain and rotation were hypothesized to be associated with the presence and extent of left ventricular myocardial fibrosis in Duchenne muscular dystrophy. Investigators recently ...
"Our study is one of very few that shows a relationship between prophylactic cardiac medication use and survival in DMD…This is a strong addition to the existing literature supporting early initiation ...
The MDA meeting is a key opportunity to highlight the expanding real‑world evidence shaping care for the Duchenne community,” said Will Andrews, MD, Chief Medical Officer of Catalyst. “Through our ...
With improved survival becoming more common among individuals who have Duchenne muscular dystrophy (DMD), cardiomyopathy is also increasing in prevalence among this population. New data from a 20-year ...
Durham-based Precision BioSciences, a gene-editing company, has received regulatory clearance to begin a clinical study of its potential treatment for Duchenne muscular dystrophy (DMD), a rare ...
Please provide your email address to receive an email when new articles are posted on . Cardiomyopathy in Duchenne muscular dystrophy possesses a unique pathophysiology. Integrated wall stress can be ...
Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients. Delandistrogene moxeparvovec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results